Q2 Earnings Forecast for FOLD Issued By Leerink Partnrs

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Amicus Therapeutics in a note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

A number of other equities analysts also recently commented on FOLD. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Price Performance

FOLD opened at $9.41 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The business has a fifty day moving average price of $9.68 and a 200 day moving average price of $10.53. Amicus Therapeutics has a 12 month low of $8.78 and a 12 month high of $14.03.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors have recently modified their holdings of FOLD. Avanza Fonder AB purchased a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $157,000. Park Avenue Securities LLC acquired a new stake in Amicus Therapeutics during the 4th quarter valued at $123,000. Diversified Trust Co increased its position in shares of Amicus Therapeutics by 9.7% during the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock worth $770,000 after acquiring an additional 7,257 shares during the last quarter. Virtu Financial LLC purchased a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $107,000. Finally, Old West Investment Management LLC increased its stake in shares of Amicus Therapeutics by 617.2% in the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after buying an additional 292,976 shares during the last quarter.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 22,901 shares of company stock worth $259,863. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.